T

The Urology Group | Cincinnati, OH

Research site
(Unclaimed)
Location
2000 Joseph E Sanker Boulevard, Cincinnati, Ohio, United States of America
Site insights

Top conditions

Prostatic Cancer (14 trials)

Urinary Incontinence (6 trials)

Urinary Bladder Cancer (4 trials)

Stress Urinary Incontinence (4 trials)

Enuresis (4 trials)

Top treatments

Androgen
Enobosarm
Darolutamide
Enzalutamide
Rucaparib
GTx-024
Apalutamide
Zoledronic Acid
Galeterone
Toremifene Citrate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

9 of 31
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (PRIMORDIUM)

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Enrolling
Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for partic...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: Investigator Choice (Gemcitabine)
Drug: Investigator Choice (Mitomycin C)

The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombi...

Active, not recruiting
Metastatic Castration Resistant Prostate Cancer
Drug: Abiraterone acetate or Enzalutamide or Docetaxel
Drug: Rucaparib

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Enrolling
Urinary Bladder Neoplasms
Biological: Cetrelimab
Drug: TAR-200

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Enrolling
Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

The purpose of the study is to assess if the addition of darolutamide to ADT compared with ADT alone would result in superior clinical efficacy in pa...

Active, not recruiting
Metastatic Hormone-sensitive Prostate Cancer
Drug: Darolutamide (BAY1841788, Nubeqa)
Other: ADT

Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects wi...

Enrolling
Lower Urinary Tract Symptoms
Urinary Bladder, Overactive
Device: INTIBIA Non-Therapeutic
Device: INTIBIA Therapeutic

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and...

Enrolling
Cancer
Drug: Darolutamide (Nubeqa, BAY1841788)

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with G...

Enrolling
Prostate Cancer
Device: Vanquish System

Trial sponsors

G

GTx (5 trials)

Bayer logo

Bayer (4 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems